Treatment of Breast Cellulitis
For breast cellulitis, first-line treatment should be oral cephalexin 500 mg 3-4 times daily or amoxicillin-clavulanate 875/125 mg twice daily for 5-6 days, with extension if symptoms do not improve. 1
Antibiotic Selection
The treatment approach should follow these guidelines:
First-line antibiotics (targeting Streptococcus and methicillin-sensitive S. aureus):
For patients requiring IV therapy:
Consider MRSA coverage when:
Special Considerations for Breast Cellulitis
Breast cellulitis has some unique characteristics, particularly following breast conservation therapy for cancer:
- Breast cellulitis following breast conservation therapy may represent a shift from the traditional upper extremity cellulitis seen after mastectomy with axillary lymph node dissection 3
- Fluid collections at the surgical lumpectomy site increase risk (83% of cases) 3
- Risk may increase following follow-up mammograms 3
For implant-based breast reconstruction cases with cellulitis:
- Oral fluoroquinolones (e.g., ciprofloxacin, levofloxacin) may be considered as first-line treatment based on institutional microbiological data 4
- If oral antibiotics fail, consider IV options like gentamicin plus vancomycin 4
Treatment Duration and Follow-up
- Standard duration is 5-6 days for uncomplicated cellulitis 1
- Extend treatment if symptoms do not improve after initial course 2
- Monitor for visible improvement in local signs (decreased erythema, swelling, tenderness) 1
- Ensure patient is afebrile for at least 24 hours without antipyretics before discontinuing treatment 1
Prevention of Complications and Recurrence
- Address predisposing factors to minimize risk of recurrence 2
- For patients with 3-4 episodes per year despite treatment of predisposing factors, consider prophylactic antibiotics:
- Oral penicillin or erythromycin twice daily for 4-52 weeks
- Intramuscular benzathine penicillin every 2-4 weeks 1
When to Consider Alternative Diagnoses
- Failure to improve with appropriate first-line antibiotics should prompt consideration for:
- Resistant organisms
- Secondary conditions that mimic cellulitis
- Underlying complicating conditions (immunosuppression, chronic liver disease, chronic kidney disease) 2
Pitfalls to Avoid
- Failing to recognize MRSA risk factors when selecting empiric therapy
- Treating for insufficient duration when symptoms persist
- Not addressing underlying predisposing factors, leading to recurrence
- Overlooking the possibility of an abscess requiring drainage (consider point-of-care ultrasound in unclear cases) 5
- Not recognizing the unique characteristics of breast cellulitis following breast conservation therapy or reconstruction 4, 3